COMBINATION OF MONALIZUMAB, DURVALUMAB, CHEMOTHERAPY AND BEVACIZUMAB OR CETUXIMAB FOR THE… Application WO-2020225552-A1 World Intellectual Property Organisation (WIPO) 12 Nov 2020